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ABSTRACT 
Canine Leishmaniosis (CanL) is a zoonotic disease caused by the protozoan parasite Leishmania 
infantum and represents a serious public health problem in many part of the world. L.infantum can be 
experimentally transmitted by whole blood or mononuclear cell fractions of infected dogs to recipient 
animals. The LiESP/QA-21 vaccine (CaniLeish®, Virbac, France) was launched in Europe in 2011. 
CaniLeish® is capable of stimulating a strong and long-lasting cell-mediated immunity that is still 
present 1 year after the last dose of primary vaccine course. The aim of this study was to continue the 
previous study led at the Veterinary Transfusion Centre, Department of Veterinary Sciences, Univer-
sity of Pisa, between February 2013 and July 2014. Serum biochemical analytes evaluation (Total 
Protein, Albumin and C Reactive Protein), serological (Speed Leish K™ and IFAT) and molecular 
(qualitative PCR) tests were assessed in a group of healthy blood donor dogs immunized with 
CaniLeish®. Canine samples were monitored during initial immunization, after 2 months and before 
the first, second and third annual booster. The results were: slight hyperproteinemia in 29.8% of cases 
no statistically significant, increase of C Reactive Protein in 60.7% of canine samples, slight statisti-
cally significant alterations in globulins fractions (among which  -1 and  -2 globulins, as absolute 
and percentage values, and γ-globulins percentage values), Speed Leish K™ assay always negative, 
increases of IFAT titres in 26.7% of cases. PCR results were negative in 92.3% of cases and positive 
in 7.7%. The observed alterations in the parameters studied were likely due to the development of 
post-vaccination immunization. In conclusion, the use of CaniLeish® vaccine could be recommended 
as an additional preventative measure and it  could represent an important practice in the field of ca-
nine transfusion medicine. 
Keywords: canine, transfusion medicine, Leishmaniasis, preventative measures, CaniLeish® 
 
RIASSUNTO 
 
La Leishmaniosi canina è una malattia zoonotica protozoaria causata da Leishmania infantum e 
rappresenta un importante problema per la salute pubblica in diverse parti del mondo. L.infantum può 
essere trasmessa sperimentalmente attraverso il sangue intero o gli emocomponenti di cani infetti ad 
animali riceventi. Il vaccino LiESP/QA-21 (CaniLeish®, Virbac, Francia) è stato lanciato in Europa 
nel 2011. CaniLeish® è capace di stimolare una forte e duratura  immunità cellulo-mediata, che 
rimane tale fino a un anno dopo l’ultima dose del primo ciclo vaccinale. L’obiettivo di questo studio 
era di continuare il lavoro iniziato nello studio precedente, condotto tra Febbraio 2013 e Luglio 2014 
presso il Centro di Trasfusione Veterinario dell’Università di Pisa (Dipartimento di Scienze 
Veterinarie). Su un gruppo di cani donatori vaccinati con CaniLeish® sono stati eseguiti una 
valutazione di alcuni analiti sierici (Proteine Totali, Albumina e Proteina C Reattiva), die test 
sierologici (Speed Leish K™ e IFAT) e di un esame molecolare (PCR qualitativa). La popolazione 
campione è stata monitorata durante il primo ciclo vaccinale, dopo due mesi e in concomitanza con il 
primo, il secondo e il terzo richiamo annuale. I risultati sono stati: leggera iperprotidemia non 
statisticamente significativa presente nel 29.8% dei casi, incremento della Proteina C Reattiva nel 
60.7% dei campioni, alterazioni statisticamente poco significative di alcune frazioni globuliniche (tra 
cui  -1 e  -2 globuline, sia valore assoluto che percentuale, e valore percentuale delle γ-globuline), 
test Speed Leish K™ sempre negativo, aumento dei titoli IFAT nel 26.7% dei casi. La PCR è risultata 
negativa nel 92.3% dei casi e positiva nel 7.7%. Le alterazioni osservate sono state dovute 
probabilmente allo sviluppo dell’immunità post-vaccinale. In conclusione, l’uso del vaccino 
CaniLeish® potrebbe essere raccomandato come ulteriore misura di profilassi e potrebbe 
rappresentare una procedura importante nel campo della medicina trasfusionale canina. 
 
Parole chiave: cane, medicina trasfusionale, Leishmaniosi, misure di profilassi,  CaniLeish® 
 
  
  
6 
 
SUMMARY 
 
Transfusion of whole blood and its derivatives is considered important for the 
survival of more than 80% of canine patients in critical conditions, restoration of 
blood volume being crucial in cases of severe anaemia and haemorrhages.
1
  
In veterinary field, transfusion medicine emerged as a practice from the 1950s 
onwards. However, the safe use of component blood therapy requires knowledge of 
blood groups and antibody prevalence, and knowledge of the means to minimize the 
risk of adverse reactions, by including the use of proper donors and screening assays 
that facilitate detection of serological incompatibility. Blood typing enables the 
practitioners to identify the blood group of the patient that needs blood transfusion or 
a candidate donor.
2
 In 2014 has been created the first national dog blood donor bank 
(DbD) that takes a census all donors being in Italy. The DbD is patronized from 
ANMVI (Associazione Nazionale Medici Veterinari Italiani) and FNOVI 
(Federazione Nazionale Ordine Veterinari Italiani), which actively contributed to the 
initiative regarding deontological and professional issues.
3
 Thousands of blood 
transfusions are performed each year on dogs and cats, and the demand for blood 
products continues to grow. Risks associated with transfusions include the risk of 
diseases transmission. Appropriate screening of blood donors for blood-borne 
infectious disease agents should be performed to reduce this risk. Geographic 
restrictions of disease and documentation of actual disease transmission by 
transfusion are factors that might need to be considered to make a decision on what 
screening program to use, in order to ensure blood safety.
4
 Among the pathogens that 
could be transmitted by blood transfusion, there is a higher risk with protozoans due 
to their long incubation period, subclinical persistence in infected animals and 
likelihood of remaining viable in blood stocks. Canine Visceral Leishmaniosis is an 
emergent disease that is expanding its range in several regions of the world and dogs 
are the most important reservoir. Dogs infected by Leishmania infantum present a 
widely variable incubation period and a large spectrum of clinical characteristics. For 
this reason the identification of infected animals gets complicated, particularly 
asymptomatic ones, that constitute nearly 40%, which represent an important parasite 
carrier when are used as donors. Leishmania infantum can be experimentally 
transmitted by whole blood or mononuclear cell fractions of infected dogs to 
7 
 
recipient animals, and this is a significant finding given the widespread use in 
veterinary medicine of blood transfusions.
1
  
All seropositive dogs, whether or not they express clinical disease, are potential 
sources of infection for vectors and may transmit the disease. In general, 
seronegative infected dogs are unlikely to be infectious to sand flies, however they 
may develop active infection, seroconvert and become infectious.
5
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GENERAL PART 
 
SECTION 1 - CANINE LEISHMANIOSIS 
 
1.1. Geographical distribution of Canine Leishmaniosis in Europe 
 
Canine Leishmaniosis (CanL) is a zoonotic disease caused in Europe by the 
protozoan parasite Leishmania infantum and represents a serious public health 
problem in many part of the world, due to its zoonotic nature. The domestic dog is 
considered the main reservoir of human infection, and phlebotomine sand flies are 
the biological vectors of the parasite.
5
  
In southern Europe, about 700 autochthonous human cases of leishmaniosis due to 
L.infantum are reported yearly and the average seroprevalence in domestic dogs is up 
to 25%. CanL is endemic in the Mediterranean basin, including the European 
countries Cyprus, Greece, Albania, Croatia, Italy, Malta, France, Spain and Portugal. 
It is also thought to be endemic in Romania, Bosnia, Macedonia, Montenegro and 
Bulgaria.
6
 There has been some recent evidence of Leishmaniosis spreading to 
previously unaffected areas. Extension of the disease distribution areas is attributed 
to changes in vector distribution, which may result from environmental changes, 
global warming, and growing world trade and animal transportation, including the 
increased mobility of dogs across borders. Previously being confined to 
Mediterranean coastal biotopes, autochthonous Leishmaniosis cases do not appear to 
be limited to these habitats anymore, exhibiting an expansions towards new biotopes 
at northern latitudes and higher altitudes. This new cases are reported Netherland, 
United Kingdom, Germany, Denmark and Hungary. Overall, CanL and also human 
Leishmaniosis cannot be regarded anymore as disease of the Mediterranean regions 
only, but of the whole of Europe.
5
 
For what concerns the epidemiological situation in Italy, until 1980s the northern 
regions were unscathed about CanL. Since the beginning of 1990s, the incidence of 
CanL has increased in each endemic region and steady micro-focuses of 
Leishmaniosis have been observed also in traditionally not infected regions, as those 
of Piemonte, Valle d ’Aosta, Lombardia, Trentino-Alto Adige, Veneto e Friuli 
Venezia Giulia.
7
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1.2. Prevalence of Canine Leishmaniosis in Europe 
 
An important epidemiological feature of CanL in endemic areas is a high prevalence 
of infection despite of a low prevalence of clinical disease. Prevalence estimates are 
highly variable, since they depend on the true prevalence and are influenced by the 
diagnostic tests that are used. Prevalence estimates are based either on parasite 
detection by Polymerase Chain Reaction (PCR) or on immunological tests. 
Seroprevalence in endemic countries is around 10%, with wide variability within 
them, as illustrated in Table 1. 
 
 
TABLE 1: Examples of prevalence of disease, seroprevalence and prevalence of L.infantum infection, 
based on both serology and molecular techniques, in different countries where CanL is endemic 
(EFSA AHAW Panel, 2015) 
 
Country N° of dogs Prevalence of 
clinical disease 
Seroprevalence Prevalence of 
infection 
(PCR)
(a)
 
France 30 0% 3% (IFAT) 80% 
 253 26% 30% (ELISA) 83% 
Greece 73 0% 12.3% (IFAT) 63% 
Spain  100 13% 26% (ELISA) 67% 
Italy 43 0% 7% (IFAT) 23% 
Cyprus 900 1.3% 14.9% (ELISA) 
11.8% (IFAT) 
25% 
(a): Different PCT methods were used. 
ELISA, enzyme-linked immunosorbent assay; IFAT, immunofluorescence antibody test 
 
However, serological tests underestimate prevalence, since only a proportion of 
infected dogs mount a detectable humoral immune response. Negative serological 
tests in healthy dogs should be interpreted with caution because infection cannot be 
ruled out.
6
  
PCR studies conducted in endemic areas have given much higher figures, with up to 
63%-80% of the dog population being positive. These figures are considered closer 
to the true prevalence of infection. On the other hand, prevalence of clinical disease 
is consistently lower than prevalence of infection. A questionnaire sent to practices in 
France, Spain, Portugal, Greece and Italy indicated the following annual percentages 
of practice-attending dogs with a confirmed veterinary diagnosis of CanL: 
10 
 
-  0,71% in France  
-  7,8% in Greece,  
-  3-4% in Spain, Italy and Portugal.  
 
In Greece, prevalence estimates range from 0,98% to 7,46% across the country. The 
prevalence rates of clinical CanL in France have an even more heterogeneous spatial 
distribution within central-northern France (close to 0%) and southern areas (1-
2,7%). CanL occurrence in non-endemic countries is probably underestimated 
because of difficulties associated with diagnosis and under-reporting; it is 
understandable considering that CanL is not a notifiable disease in most European 
countries. Within these ones, suspected autochthonous cases of CanL were recorded 
in Germany, Hungary and Romania.
5
 The increasing of CanL in these northern 
latitudes, where sand flies are not found or have very low densities, may be also a 
consequence of dogs travelling to or rehoming of stray dogs from endemic areas.
6
 
Many studies confirmed the high prevalence of Leishmania infection in 
asymptomatic dogs, which may act as carriers of Leishmania in the studied endemic 
areas for CanL, and may have a potential role in the establishment of domestic 
transmission cycle of the parasite.
8
  
 
 
1.3. Target species of L.infantum 
 
Dogs are the main domestic host species infected by L.infantum in endemic areas, 
and it is widely accepted that they represent the main domestic reservoir host.
5
  
This fundamental point is sustained by the high prevalence of canine infection in 
endemic areas and the infectiousness of dogs to sand flies. Instead, the role of other 
mammals is restricted to that of secondary reservoirs or occasional hosts with limited 
epidemiological relevance. This is the case of  red fox, golden jackal, wolf, hare, 
rabbit, black and brown rat, mouse
9
; domestic cats can be infected by L.infantum, but 
clinical manifestations are rare and, when present, have many similarities with 
CanL.
5
  
In European countries or regions where L.infantum is endemic, Leishmaniosis 
represents an important zoonosis for humans, especially young children and 
immunocompromised adults. Prevalence of infection in dogs has been suggested as a 
11 
 
marker of the transmission risk of L. infantum to the susceptible human population.
9
 
As with CanL, the number of subclinically infected persons in endemic areas exceeds 
largely the number of clinical cases.
5
 An increasing number of companion animals 
and humans is therefore expected to be at risk of leishmaniosis, and this is a 
challenge that requires a global “One Health” approach.6 
 
 
1.4. Life cycle 
 
Sand flies acquire the parasite during a blood meal via of mononuclear cells infected 
by amastigotes. In the sand flies, amastigotes transform into procyclic promastigotes 
and then into infectious metacyclic promastigotes within four or five days. Infectious 
promastigotes invade than phariynx and proboscis of the vector and therefore they 
can be inoculated into a new host.
5
 The need to counteract the host's hemostasis led 
the evolution in sand flies of salivary antihemostatic compounds, as well as 
vasodilatory substances, that are injected in.
10
 Sand flies become infectious at least 
one week after taking an infective blood. In the host, promastigotes are rapidly 
phagocytosed by macrophages in the upper dermis; in these cells differentiate into 
amastigote forms within hours, multiply and disseminate to various organs by means 
of own macrophages or dendritic cells. Intracellular amastigotes represent the 
infective form for the vector and can be taken up by a new sand fly during blood 
feeding even several months after initial bite.
5
  
 
 
1.5. Modalities of transmission 
 
The main route of transmission of Leishmania infantum to mammals is via bite of 
female sand flies belonging to the genus Phlebotomus. Phlebotomus perniciosus and 
Phlebotomus ariasi have been incriminated as vectors in Portugal, Spain and France, 
and the former is also the most widespread vector in Italy.
9
 Since DNA of L. 
infantum has been detected in larvae from infected females, the tick Rhipicephalus 
sanguineus have been evaluated as potential vector of Leishmania, but these findings 
have not been confirmed under natural conditions.
5
 In the Mediterranean area sand 
flies have a seasonal pattern, typically from spring to autumn because their range of 
12 
 
activity is between 15°C and 28°C in association with high relative humidity. 
Transmission is mainly rural and occurs especially around the urban areas, near 
homes with yard or garden where live dogs and in the presence of conditions 
favouring the settlement of sand flies, as accumulated rubbish or decomposing 
organic material. Adults are mainly active in the early morning, in the evening and at 
night, but they can bite also during the day. They feed on dogs principally in skin 
areas with a reduced hair coat, such as the head, nasal bridge, ear pinnae and inguinal 
and perineal areas.
9
 
Although lesser common, have been reported alternative routes of horizontal and 
vertical transmission of L.infantum. Transmission of the parasite by blood transfusion 
is almost ascertained both in human species
 
and in canine that one.
4
 Indeed, in the 
study managed by de Freitas et al. (2006), processed blood of nineteen Leishmania-
seropositive adult dogs was inoculated intraperitoneally in 6-8-week-old female 
hamsters, which six months after inoculation showed clinical symptoms compatible 
with visceral Leishmaniosis and furthermore seropositivity.
1
 
The frequency of vertical transmission in endemic areas is unknown due to the 
considerable likelihood of exposure to vectors. However, congenital transmission of 
visceral Leishmaniosis is reported in humans and appears likely also in dogs, 
considering the results of the study managed by Rosypal et al. (2005); in this 
mentioned study, four female and one male beagles were experimentally infected 
with an isolate of L.infantum and then were mated. L.infantum DNA was detected by 
PCR in several tissues sampled from puppies recently or just born.
11
  
Under these circumstances, infected females should not be used for reproductive 
purposes, because of the potential risk of transmission of the parasite to their 
offspring.
9
 
Venereal transmission of Canine Visceral Leishmaniosis was supposed because a 
high number of infected dogs was observed in an area with low vector population 
and low number of human cases, and this finding is not compatible with exclusively 
vector-mediated transmission. The researches of Diniz et al. (2005) have reported 
detection of amastigote forms of Leishmania sp. in genital organs and in the semen 
of dogs with visceral Leishmaniosis, in addition to genital lesions associated with the 
disease.
12
 Direct dog-to-dog contact has been suggested as possible responsible for 
transmission of Leishmaniosis, because of the CanL outbreak amongst Foxhounds in 
US and Canada in the absence of known competent vectors.
13
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1.6. Clinical illness 
 
Dogs are highly susceptible to infection by L.infantum, and CanL is a potentially 
severe and fatal disease, although the outcome of the infection is highly variable. 
Clinical signs have been observed as early as six months of age, but often it takes 
more than a year for a susceptible dog to develop the first clinical signs or 
clinicopathological abnormalities following natural exposure to infected sand flies 
bites. The CanL may evolve from asymptomatic cases to a systemic disease. When 
clinically expressed, L.infantum infection in dogs can be displayed as a chronic self-
limiting or a severe not-self-limiting disease. Because of the wide presentations of 
clinical illness, the LeishVet group have proposed four clinical stages to simplify the 
overview of the disease and to establish treatments and prognosis for each stage.
5
 
Skin lesions are the clinical signs mostly showed in infected dogs, and are 
represented by alopecia, exfoliative dermatitis, ulcerative dermatitis, nodules papules 
and pustules, and onychogryphosis. From the localized cutaneous infection, the 
parasite can be disseminated via lymphatic or blood vessels and the infection can 
results in a systemic disease.
14
 
Sick dogs may go through different clinical stages during their lifetime with 
individual differences. A deficiency in one or more components of the immune 
system, such as neoplasia, immunosuppressive drugs and old age, may trigger the 
transition to more several clinical stages. Glomerulonephritis and proteinuria are 
frequently reported in CanL in the range from 10 to 30% of the total number of sick 
dogs.
5
  
Renal disease may be the sole clinical manifestation of CanL and it can progress 
from mild proteinuria to the nephrotic syndrome or to an end-stage renal disease. 
Other signs such as fever, diarrhea, intestinal hemorrhage, hepatosplenomegaly, 
hyperkeratosis, cutaneus ulcerations -particularly on the periorbital and nasal areas-, 
keratoconjunctivitis and lameness due to polyarthritis  have also been reported, 
although not necessarily present in all animals. Weight loss and lymph node 
enlargement are the earliest and most frequently observed signs, followed by 
cutaneous abnormalities and then ocular signs.
15
 
There is relatively few data on mortality rates and survival time in dogs which 
showed clinical CanL. From a survey conducted in France in 2004 on infected and 
treated dogs is resulted that:  
14 
 
- 22,5% of dogs survived less than one year  
- 13,5% survived one to two years 
- 35,7% survived two to five years 
- 30,3% survived for more than five years 5 
 
As revealed in advance, four stages of CanL are defined on the base of dog’s 
serological status, clinical signs and laboratory findings. Instead, the assessment of 
disease severity is mainly based on the evidence of renal disease through laboratory 
findings: 
- Stage I : absence of evident renal disease (mild disease) 
- Stage II : presence of a very mild proteinuria (moderate disease) 
- Stage III : chronic kidney disease IRIS stage I or II, on the base of azotaemia 
and proteinuria values (severe disease) 
- Stage IV : chronic kidney disease IRIS stage III or IV (very severe disease)  
This system of four clinical stages has been defined with the aim to cover the wide 
spectrum of clinical manifestations and degrees of severity found in CanL.
15
 
Two methods of patient’s classification have been adopted by Canine Leishmaniasis 
Working Group (CLWG) and Leishvet Group to try to set the disease in its evolutive 
stage, both to allow adequate therapy and to prevent possible development towards 
more severe or irreversible phases.  
As reported below, the dogs could be considered exposed, infected or sick. 
- Exposed dogs: they are defined as “exposed” those dogs clinically healthy, 
with negative cyto-histologic, parasitologic and molecular diagnostic tests, 
and with specific antibody titres not higher than fourfold of threshold value of 
the reference laboratory. 
- Infected dogs: they are defined as “infected” those dogs which show presence 
of parasite, demonstrable with direct and indirect methods. 
- Sick dogs: as a general rule, an infected dog can be defined “sick” in two 
situations; when it shows one or more clinical signs suggestive of 
Leishmaniasis from those reported above, or when it shows hematological, 
hematochemical and urinary alterations that can be related to Leishmaniasis, 
even in absence of detectable clinical signs.
7
 
The most frequent laboratory changes are reported in the following section. 
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1.7. Haemato-Biochemical alterations 
 
The haematological and biochemical alterations mostly detected in naturally or 
experimentally infected dogs are evidenced by the basic laboratory tests, namely 
Complete Blood Count (CBC), Serum Biochemical Profile (SBP), Coagulation 
Status (CS), Serum Protein Electrophoresis (SPE), and Urinalysis (UA). 
The main findings compatible with Leishmaniosis include: 
- Non regenerative/scarcely regenerative anaemia 
- Stress/inflammatory leukogram pattern with neutrophilia-monocytosis and 
lymphopenia-eosinopenia 
- Leukopenia 
- Thrombocytopenia 
- Hyperfibrinogenemia, prolongation of the PT and aPTT 
- Hyperproteinemia, hypoalbuminemia, hyperglobulinemia (mostly alpha-2 
globulins) and alteration of Albumin/Globulin ratio 
- Polyclonal/Oligoclonal gammopathy 
- Azotemia with increasing of BUN and serum Creatinine 
- Increasing of liver enzymes 
- Hyposthenuria/Scarcely concentrated urines 
- Proteinuria 
In accordance with a study conducted by A.B. Reis et al., the clinical evolution of 
CanL in naturally infected dogs promotes alterations in serological, parasitological 
and haemato-biochemical parameters, which are directly correlated with the clinical 
status. These findings reveal that the evaluation of laboratory aspects, associated with 
clinical examination, contribute importantly both in diagnosis of Leishmaniosis and 
in follow-up of dogs during infection.
7, 14
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SECTION 2 – PERFORMANCE OF THE MAIN DIAGNOSTIC TESTS 
 
2.1. Main available diagnostic tests 
 
Diagnosis of Canine Leishmaniosis is usually performed to confirm disease in dogs 
with compatible clinical signs or clinicopathological abnormalities. However, 
detection of infection may also be achieved for monitoring the progression of 
disease, for screening clinically healthy dogs living in endemic regions, to prevent 
transmission by blood transfusion and to observe response to treatment.
5
 
When CanL is considered among possible differential diagnosis on the base of 
history, physical examination and routine laboratory tests, a definitive proof of the 
infection is the next necessary step. Unfortunately, CanL diagnosis is still a challenge 
because of possible overuse, underuse and/or misinterpretation of some test results.
16
  
Equal importance should be given to both the efficacy of the laboratory tests used 
and the choice of biological material. A gold standard technique should have high 
sensitivity and specificity, must be reproducible, easy to perform, should have costs 
contained, should be non-invasive, and should detect all infected dogs in an initial 
stage of the disease. In spite of improvements made in the development of several 
parasitological, serological and molecular techniques, more researches are required 
to achieve all these objectives.
17
  
On the base of the increased incidence of Canine Leishmaniosis in the last decade, 
additionally to intense cutaneous parasite density in infected dogs which may 
contribute to the urban spread of disease, it must be considered highly relevant 
epidemiologically. Therefore, precise diagnosis of CanL has crucial importance.
18
  
The diagnostic workup takes advantage of direct and indirect laboratory techniques.  
 
The main direct diagnostics include 
- Microscopic examination: it allows observation of Leishmania amastigotes in 
stained smears from samples of infected organs/tissues, namely bone marrow, 
lymph nodes, skin, or rarely peripheral blood. Amastigotes could be found 
free or intracellularly in monocytes, macrophages and neutrophils, in smears 
stained with Romanovsky-based stain. The main limit of this method is re-
lated to the overly invasive procedure to obtain samplings, which generally is 
not useful for detection of the parasite in asymptomatic dogs. Furthermore, 
17 
 
density of amastigotes in each sampling is often variable, and this fact may 
decrease the sensitivity of the method.
17
  
In conclusion, the diagnostic sensitivity of cytology depends on the quality of the 
preparation, the skills of the examiner, the time devoted to observation and 
microscope fields evaluated.
16
 
 
- Histopathology: this technique is also used to detect the presence of amas-
tigotes in infected organs stained with Hematoxylin-Eosin. Popliteal lymph 
nodes material resulted to be the most effective both in asymptomatic and in 
symptomatic dogs, followed by spleen and bone marrow. However, this 
method has low sensitivity because of the difficult recognition of parasites.
17 
 
- Immunohistochemistry: immunoperoxidase or direct immunofluorescence of 
tissues can be used as a supplementary tool to confirm the diagnosis made 
with Hematoxylin-Eosin stain, especially in organs which do not present high 
parasite load. It is important to take into consideration that also Immunohis-
tochemistry, such as Microscopic observation and Histopathology, could give 
way to false negative results because their sensitivity depends on the parasite 
load.
17 
 
- Culture: although 100% specific, the culture of different infected tissues is 
now-a-day less used for diagnosis owing to delay in the results, susceptibility 
to false positive for microbiological contamination, dependence on the para-
site load and sometimes scarce adaptation of isolate to medium used.
17 
 
- Molecular techniques: include Polymerase Chain Reaction (PCR), nested 
PCR and real-time PCR. These procedures are used with increasing fre-
quency for the diagnosis of CanL, and are based on the detection of Leishma-
nia DNA. Molecular methods can be carried out with a wide range of clinical 
samplings, namely whole blood, buffy coat, bone marrow, lymph nodes, skin 
or conjunctiva swabs. Studies evaluating PCR from different tissues of in-
fected dogs have shown variable results, that could be explained by the het-
erogeneous distribution of the parasites in each tissue, Leishmania strain’s 
tropism and local immune response.
16, 17 
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For what concerns the indirect diagnosis of CanL, it is based on the humoral 
immunity. Detection of Leishmania-specific IgG antibodies through several 
quantitative serological tests is widely and commonly used as approach for diagnosis 
of CanL.
16, 17
 Seroconversion occurs in a period that ranges from 1 month to 22 
months (on average 5 months) for natural infections, and from 1 month to 6 months 
(on average 3 months) for experimental ones.
7
 
Generally, specific humoral response in Canine Leishmaniosis presents very high 
levels of specific immunoglobulins that increase over time.  The sensitivity of these 
tests is typically elevated because of the excessive, but non-protective, humoral 
immune response in infected dogs. However, the only detection of high IgG level 
could not be a conclusive sign of disease, considering that it may also indicate the 
presence of another disease.
16, 17
 
The main serological tests include 
- IFAT: the Indirect Immunofluorescence Antibody Test represents the “gold 
standard” of indirect diagnostics and it uses whole body of amastigotes as an-
tigen. However, there are several limitations for its use, since there are re-
quired an high level of experience and expensive laboratory facilities, and be-
cause the serial dilutions of serum make the test not practical for screening of 
large number of samples.
17 
 
- ELISA: Enzyme-Linked Immunosorbent Assay is useful for screening a large 
number of samples since it is simple to perform and various antigens could be 
used, such as whole cytoplasmatic, purified antigens, defined synthetic pep-
tides and recombinant proteins. In a study performed in 2006 it has been 
demonstrated that the choice of Leishmania species to use for antigen prepa-
ration may significantly influence the result of ELISA and consequently the 
diagnosis of CanL. According to a study conducted in 2005 by Mettler et al., 
ELISA test based on soluble promastigote or amastigote antigens has shown 
high sensitivity both in asymptomatic and symptomatic dogs (respectively 
94,1-100% and 100%).
17
 However, cross-reactivity with other canine diseases 
have also been reported.
18 
 
- Immunochromatographic Rapid Test: several kind of rapid immunochroma-
tographic test kits are available on the marketplace. Actually, one of the most 
19 
 
popular test-kits for diagnosis of CanL is represented by Speed Leish K ® (BVT 
Groupe Virbac, La Seyen sur Mer, France). It is a dipstick device to detect anti-
Leishmania infantum antibodies and it is based on an immunochromatographic 
principle. This test-kit uses a complex of recombinant kinesins as antigen. It is 
simple to use and has very quick response times. It has shown good sensitivity 
and specificity, which seem to increase at a 30-minutes reading rather than at a 
20-minutes reading. Speed Leish K ® appears useful for the assessment of the 
infection when the IFAT reveals uncertain titres (1:40-1:80) and to distinguish 
infected dogs from vaccinated ones, because this test does not detect antibodies 
inducted by vaccination.
19
 
 
 
2.1.1.  IFAT 
 
IFAT is performed putting into contact the serum to evaluate with Leishmania 
promastigotes in order to detect the possible presence of specific antibodies. If they 
are present, the bond between specific antibodies and Leishmania promastigotes is 
revealed through the use of fluorescein isothiocyanate conjugated anti-antibodies. 
Serial dilutions of serum to analyze must be done to determine antibody titre and 
must be performed until the last positive dilution (“end point” titration). Broadly, 
antibody titre determination allows to distinguish infected but healthy dogs, which 
have a tendency to low titres, from sick ones with parasite dissemination, that have a 
tendency to high titres. For what concerns the threshold values, most of reference 
laboratories consider negative IFAT titres lower than 1:40, positive IFAT titres equal 
or higher than 1:80, and doubt that ones from 1:40 to 1:80.  
At any rate, considering that serological studies are characterized by a high 
coefficient of variation inter-and intra-assay, it is suitable to consider as high only 
titres exceeding at least fourfold difference with threshold value of positivity for the 
reference laboratory. IFAT sensitivity and specificity are resulted near 100%, 
therefore World Organization for Animal Health (OIE: Office International des 
Epizooties) considers this test as reference serologic method.
7
  
However, although IFAT is the most widespread diagnostic test, it presents also some 
limitations, such as a relatively low sensitivity in detecting asymptomatic dogs, the 
usually late seroconversion and the inability to discern between seropositivity 
20 
 
induced by vaccines, in endemic areas where the anti-CanL vaccination has already 
become a common practice, and that one consequent to natural infection.
18
 
 
 
2.1.2. Immunochromatographic assay (Speed Leish K™)  
 
Speed Leish K™ is a rapid immunochromatographic test that allows to determine the 
serological status of a dog toward Leishmaniasis. It detects circulating antibodies 
directed against the kinesins of Leishmania infantum through a Kinesin Capture 
Complex. Recombinant proteins that present high immunogenic capacity during all 
stages of infection represent this Complex. 
It has been demonstrated that in comparison to the reference method, represented by 
Immunofluorescence Assay (IFA), Speed Leish K™ shows 98% sensitivity, 100% 
specificity and 98,5% diagnostic efficiency.  The diagnostic efficiency is a parameter 
that defines the percentage of positive and negative results in accordance to the 
reference method, and it is calculated with the following formula:  
 
                             
                  
 
 
The use of selected recombinant proteins assures an optimal specificity of Speed 
Leish K™ that allows to avoid possible cross-reactions and so false positive results. 
Speed Leish K™ detects specifically antibodies against the kinesins of Leishmania, 
which are not present in Excreted-Secreted Proteins (ESP) of CaniLeish® vaccine. 
Therefore, Speed Leish K™ allows both to evaluate the absence of anti-Leishmania 
antibodies before starting the first vaccination cycle and does not detect the 
antibodies induced by the vaccine.
19, 42
  
The protective effect of CaniLeish® vaccine has not been studied in already infected 
dogs by Leishmania infantum, therefore
 
any positivity showed by Speed Leish K™ 
should be an exclusion cause from administration of the vaccine.
39,42 
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2.1.3.  PCR 
 
PCR is an enzymatic assay, which allows for the amplification of a specific DNA 
fragment from a complex pool of DNA. PCR can be performed using source DNA 
from a variety of tissues and organisms, including peripheral blood, skin, hair and 
saliva. Just few amounts of DNA are needed for PCR to generate enough copies to be 
analyzed through conventional laboratory methods. Each PCR assay requires the 
presence of template DNA, primers, nucleotides, and DNA polymerase. The DNA 
polymerase is the key enzyme that links individual nucleotides together to create the 
PCR product. The nucleotides include the four bases (Adenine, Thymine, Cytosine, 
Guanine) that constitute DNA. The primers specify the exact DNA product to be 
amplified. The primers are short DNA fragments with a defined sequence 
complementary to the target DNA that is to be detected and amplified.  
There are two main methods of visualizing the PCR products: staining the amplified 
DNA product with a chemical dye, such as Ethidium Bromide, which intercalates 
between the two strands of the duplex, or marking the PCR primers or nucleotides 
with fluorescent dyes (Fluorophores) prior to PCR amplification. The latter method 
allows the labels to be directly incorporated in the PCR product. The most widely 
used method for analyzing the PCR product is the use of agarose gel electrophoresis, 
which separates DNA products on the basis of size and charge. Agarose gel 
electrophoresis is the easiest method of visualizing and analyzing the PCR product. A 
predetermined set of DNA products with known sizes are run simultaneously on the 
gel as standardized molecular markers, which are useful to determine the size of the 
product.  
Typically, when PCR is used to detect the presence or absence of a specific DNA 
product, it is called qualitative PCR. Qualitative PCR is a good technique to use 
when PCR is performed for cloning purposes or to identify a pathogen. 
Quantitative real-time or qRT-PCR provides information beyond mere detection of 
DNA. It indicates how much of a specific DNA or gene is present in the sample. 
qRT-PCR allows for both detection and quantification of the PCR product in real-
time, while it is being synthesized. 
Although PCR is a valuable technique, it presents some limitations. Since PCR is a 
highly sensitive technique, any form of contamination of the sample by even trace 
amounts of DNA can produce misleading results. In addition, some prior sequence 
22 
 
data is needed to design primers for PCR. Therefore, PCR can only be used to 
identify the presence or absence of a known pathogen or gene.
20
  
  
Accurate diagnosis of Canine Leishmaniasis requires an integrated approach, 
resorting to physical examination, haematological and biochemical tests and several 
direct methodologies. Identification of the parasites in organs presenting lesions 
compatible with Leishmaniasis allows to affirm that with good probability exists a 
cause-effect relationship between parasite and lesions.
7
 
The use of molecular techniques allows to circumvent many of the problems related 
to serological diagnosis previously mentioned. PCR helps to define infection status 
and can be useful to diagnose an acute infection and to monitor the course of disease 
after treatment. Concerning qPCR (quantitative PCR), it is more likely that high 
loads of parasite are related to illness than low loads of that one. Nevertheless, the 
detection of DNA of Leishmania not always represents clinical disease, but may also 
show the presence of unviable organisms.
21
 
Different PCR assays have been developed and they can be performed on DNA 
obtained from several tissue-samples. Besides histopathological specimens, in case 
of generalized disease other tissues can be used with a high probability to identify 
Leishmania DNA; they include bone marrow/lymph nodes, skin, conjunctive, buffy 
coat and peripheral blood. PCR is a laboratory method that allows to amplify specific 
sequences either of genomic DNA of Leishmania and kinetoplastic DNA of the same 
one, so it permits to identify very low amount of DNA of protozoans present in the 
examined biological material.
5, 7
 
The three most common used techniques are: 
- Conventional PCR: it uses a couple of primers (base sequences complemen-
tary to target sequence of examined DNA) to amplify Leishmania DNA.
7 
- Nested PCR: it is a modification of conventional PCR that involves two sets 
of primers used in two successive runs of polymerase chain reaction. Increas-
ing the number of passages, the sensitivity increases but specificity dimin-
ishes because the risk of contamination by foreign DNA and thus possible 
false-positive results rise.
7 
- Quantitative PCR (Real Time PCR): this technique allows to quantify the 
number of DNA copies present in the examined biologic sample by the use of 
fluorescent probes. This test can be useful during monitoring of disease.
7 
23 
 
As a general rule, it is advisable to resort to this test when cytologic, histologic and 
serologic studies are negative despite a strong diagnostic suspect.
7, 21
 
The selection of the sample for PCR assay is a very important matter. Lymph node 
biopsy has high sensitivity, but sampling could be not easy in absence of 
lymphoadenomegaly; bone marrow aspirates are an appropriate alternative, but 
collection is very invasive. Since the skin has been stated that is the main tissue 
reserve of Leishmania in dogs, the use of skin biopsies for PCR analysis also reveals 
high sensitivity when compared with bone marrow. Instead, the sensitivity obtained 
from blood sample is lower when compared with the other tissues. Recently, has 
been proposed the use of hair as sample considering the advantages over other 
methods, namely more simple collection, transporting and storing, as well as non-
invasive sampling. Hair seem to sequester and remove a large amounts of parasite 
kDNA, so it could be useful to detect Leishmania DNA.
22
 
 
 
2.2. Practical approach to diagnosis of CanL 
 
The spread of Canine Leishmaniasis in the continental regions of Europe represents a 
relevant risk to human and animal health. Indeed, autochthonous cases of Human 
Visceral Leishmaniasis were recently reported in areas where CanL is newly 
endemic.
19 
For what concerns veterinary practice, the managing of CanL constitutes a 
challenge, considering the variability of incubation period, ranging from three 
months to several years, and the wide spectrum of its clinical features, that vary from 
a total absence of symptoms to a severe syndrome leading to death due to a chronic 
kidney disease.
16, 21
 
Furthermore, blood transfusion medicine is a situation always more actual and 
popular in veterinary practice. Several studies have shown that Leishmania can be 
transmitted both by whole blood/ mononuclear fractions and by plasma transfusion, 
irrespective of clinical condition of donor. Therefore, it is important to highlight that 
even asymptomatic dogs can be infective.
21
 
Hence, it clearly appears that an early and accurate diagnosis represents the most 
important tool for an effective management of disease and for a significant decrease 
of the risk for human health.
19
  
On the other hand, an appropriate infectious disease screening presents several 
24 
 
complications because of variable incidence of different diseases, existence of 
chronic carrier states, difficulty in choosing a suitable screening test and lastly testing 
costs.
21
 
To reach the diagnosis of Leishmaniasis, an integrate approach among signalment, 
history, clinical signs and laboratory tests results is indispensable.
7, 21
 
As a general rule, in cases where clinical signs and alteration of basic laboratory tests 
are compatible with CanL, PCR, serology and cytology all have a high sensitivity. 
Therefore, in dogs that present consistent features the overall diagnostic approach 
that allows to formulate the diagnosis of CanL is reported below as a simplified 
algorithm.
7, 16
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Figure 1: A simplified algorithm for the diagnosis of CanL.7, 16 
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SECTION 3 – PREVENTATIVE MEASURES 
 
3.1. Objectives 
 
Leishmania infantum is the etiological agent of human and canine visceral 
Leishmaniasis in wide areas of Americas, Asia, Africa and Europe. As above-
mentioned, this vector-borne zoonotic disease is endemic in southern Europe, but is 
spreading northwards, and some new autochthonous cases are reported in previously 
CanL free areas.
6, 9
  
The growing world trade and animal transportation are some of the factors that 
contribute to spread of Leishmaniasis.
9
 Taking into account the variable clinical 
manifestations of the disease, the wide range of incubation period and the capability 
of asymptomatic dogs to be infective, it is clearly deduced that managing of CanL 
has become a challenge. Therefore, resorting to preventative measures is 
indispensable to avoid infection in individual dogs, parasite spreading by sick dogs 
and re-infection of infected ones.
5, 8, 23 
 
 
3.2. Topical products 
 
The available preventative measures are basically directed to avoid or at least to 
reduce sand fly bites by the use of specific repellent products. The insecticides 
belonging to pyrethroid family, such as deltamethrin, permethrin and flumethrin, are 
the only proven-efficacy biocides against vectors of Leishmaniasis. In addition to “no 
feeding” effect, achieved by quick and paralyzing action, they have also a secondary 
insecticide effect that is useful in cases where any sand flies are able to feed on the 
treated dogs (the percentage of insect mortality widely ranges from 18 to 91%). 
5, 23
  
Several formulations of topical products are available on the marketplace and 
include: 
- Spray: they have been shown to be active experimentally in preventing sand 
flies bites for 2-3 weeks. After application, the active principle spreads to 
whole body and it is immediately protective.
5, 23
 
- Collars: it has been demonstrated that deltamethrin collars and combining 
imidacloprid and flumethrin that ones have a protective effect. This is a slow 
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release formulation, so one week is needed to obtain full protection. The av-
erage of efficacy duration is around 6 months.
5, 23
 
- Spot-on devices: the application of drops on the back entails that the active 
principle diffusion on the whole body surface is completed after 24-48 
hours.
23
 It has been shown that spot-on preventives have a significant protec-
tive effect against CanL.
5
 
 
 
3.3. Vaccination 
 
3.3.1. Objectives 
 
Although the available topical repellent and insecticide products have good short-
term efficacy for the reduction of the disease incidence, they may not maintain it 
over longer term. Therefore, additional preventative measures are required.
24, 25, 26
  
Considering that the prevention of infection represents an unlikely achievable goal of 
CanL vaccination, more realistic objectives of that one include 
- Reduction of infection rate  
- Reduction of infectiousness of dogs for sand flies by decrease of parasite 
load, in case dogs become infected despite vaccination 
- Protection against the clinical illness in infected dogs 
Finally, those objectives aim at the reduction of L.infantum reservoir to safeguard 
both animal and human health.
5, 25 
 
 
3.3.2. Protective immunity 
 
The outcome of infection with L.infantum is highly variable and not all infected dogs 
develop the disease. Some of them remain asymptomatic, other ones present just a 
subclinical infection, while some dogs develop clinical disease of varying severity. 
Several studies have let it be clear that the final outcome of infection depends mainly 
on the efficiency and nature of the dog’s immune response.24, 26, 27 
It is now generally accepted that resistance to CanL is primarily dependent on dog’s 
capability of developing an appropriate predominant Th1 cell-mediated immune 
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response in an overall balance between the Th1 and Th2 profiles.
26, 27, 28, 29  
It seems that the protective response is primarily mediated by the induction of 
inducible Nitric Oxide Synthase (iNOS) in macrophages upon stimulation by Th1 
cytokines (IL-12, IFN-γ, IL2 and TNFα). On the other hand, active disease is 
characterized by a marked humoral response, mediated by Th2 cytokines such as 
IL4, IL5, IL10, IL13 and TNFβ.26, 28, 30 
The induction of iNOS results in a decreased production of the polyamides which are 
essential for the growth and survival of the parasite within the macrophage; 
moreover, it is demonstrated that Nitric Oxide (NO) has a direct leishmanicidal effect 
and it is also probable  that NO may have additional immunoregulatory roles.
26, 27, 31 
The iNOS expression has been found in the skin and draining lymph nodes and leads 
to a decrease of the parasites load.
32 
Macrophages, Natural killer (NK) cells, CD4
+
 and CD8
+
 T cells, cytokines (mainly 
IL12 and IFN-γ) and Nitric Oxide (NO) play a decisive role in the immune response 
against L.infantum. IL12 represents a key cytokine for the development of protective 
immunity because of its capability to activate NK cells and CD8
+
 T cells and to drive 
differentiation of CD4
+
 T cells into Th1 cells, which leads to the production of IFN-
γ.30  The expression of IFN-γ seems to be correlated with disease resistance.24 
On the other hand, susceptibility to infection may be due to the highest induction of 
regulatory cytokines such as TNFβ and IL10 that have been associated with 
significant inhibition of the macrophages efficiency in the clearance of parasites.
32
 
For what concerns the isotype patterns during CanL, it has been observed that 
asymptomatic dogs and those with low parasitism show an increase of IgG1, while 
the symptomatic ones and those with high parasitism are associated with an increase 
of IgG2, IgM, IgA and IgE immunoglobulins.
 
Furthermore, it has been demonstrated 
both that skin and spleen are the main sites with high parasite density and that bone 
marrow and spleen parasite load are the most reliable parasitological markers to 
decode the clinical status of CanL.
33
 
The innate skin immunity is the first line of defence against Leishmania infection and 
it acts through a non-specific antigen recognition. Following their inoculation into 
dermis during the sand fly blood-feeding, Leishmania promastigotes adhere quickly 
to Antigen Presenting Cells (APCs) of the monocyte/macrophage line and also to 
dendritic and Langerhan’s cells.34 
 
29 
 
Among the first cells that arrive at the site of promastigotes inoculation, neutrophils 
and macrophages are included. Their recruitment is allowed by the activated Toll-like 
receptors (TLRs) on dermal dendritic cells, which are the prototype for receptors 
which recognize pathogen-related structures and lead to production of IL8.
31, 34 
The main mechanism with which neutrophils and macrophages eliminate the parasite 
is represented by phagocytosis and following generation of phagolysosome. The 
fusion between phagosome covering the parasite and the lysosome leads to the 
activation of oxidative burst through the NO production driven by iNOS.
34, 35 
IFN-γ, that is mainly produced by Th1 CD4+ T cells, is indispensable for activation 
of the above mentioned mechanism that represent the cornerstone of resistance 
against L.infantum in infected dogs.
31, 34, 35 
Indeed, Th1 cells activate the infected macrophages to kill the parasite through the 
production of IL12 and IFN-γ, whereas Th2 cells divert to humoral immune response 
that results in the production of an excessive antibody load and IL4, that down 
regulates cellular immunity.
34
 
The survival mechanisms effected by L.infantum essentially include: 
- Escape from the phagosome into cell cytoplasm 
- Blockade of the fusion between phagosome and lysosome 
- Inhibition of the oxidative burst induction 
Furthermore, since IL8 can mediate apoptosis delay of neutrophils, it is possible that 
pathogen-induced IL8 delay PMN apoptosis up to 2 days after infection. In this way, 
L.infantum could use granulocytes to invade their definitive host cells, represented by 
macrophages, through a “Trojan horse” mechanism.35 
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3.3.3. Available vaccines 
 
In Brazil, after the strong outbreak of Human Visceral Leishmaniasis (HVL) in 2011, 
since dogs are considered the main reservoir of infection in urban areas, government 
attempted to control VL by the culling of seropositive ones. However, in addition to 
being anti-ethical procedure, this method has not been able to contain the spreading 
disease. As a consequence of research, Brazil has been the first country in the world 
to launch commercially available vaccines against CanL.
36
 
The complex antigenicity, highly variable response by the host, existing different 
species of Leishmania and costs represent the major obstacles in the development of 
vaccine against Leishmaniasis.
 
The first generation of antileishmanial vaccines used 
killed or live attenuated parasites as antigens, but they showed objectionable side 
effects resulting into clinical complication. Therefore, other antigens have been 
explored to develop a promising vaccine candidate against Leishmaniasis.
28
 
Later two generations of antileishmanial vaccines are recognized and they are 
distinguished by the immunogen which is used: 
- Leishmune®: it represents one of the two second generation vaccines that are 
available in Brazil. Leishmune® is based on the fucose-mannose ligand puri-
fied fraction from L.donovani (the etiological agent of anthroponotic Visceral 
Leishmaniasis) in association with a saponin adjuvant.
28, 36, 37
  
Leishmune® induced an immunological pattern characterized by enhanced 
levels of IFN-γ, NO, and anti-L. chagasi IgG2 , the early and persistent 
activation of neutrophils and monocytes, and increased the CD8+ T-cells 
expressing IFN-γ. This increase of CD8+ T-cells is expected for the QS21 
saponin adjuvant of Leishmune®. Leishmune® also induced early 
phenotypic changes in neutrophils and monocytes, CD8+ T-cell activation, 
and a selective proinflammatory pattern (IFN-γ/NO).38 It demonstrated 76% 
efficacy against clinical illness or death, and showed an evident Th1 immune 
response.
28
  
- Leish-Tec®: it is the other antileishmanial vaccine belonging to second gen-
eration of than ones, and it is commercialized in Brazil. Leish-Tec® is com-
posed of a Leishmania infantum recombinant protein, represented by the A2 
antigen, and saponin as adjuvant.
36, 37
 It showed 43% protection against 
Leishmaniasis in an artificial challenge model.
37
 A more recent review noted 
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unpublished data that suggest 71% efficacy against a culture positive state in 
a field study.
24 
Leish-Tec® induces a less strong humoral response in com-
parison with the response triggered by Leishmune®, but exhibits higher fre-
quency and intensity of adverse reactions.
36
 Nevertheless, while protection 
due to the Leishmune® vaccine has been extensively investigated in 
laboratory models, explained through an immunological approach, and 
presents several published reports, there is only one report of an experimental 
kennel assay with Leish-Tec® which was tested on seven dogs and compared 
with four untreated controls. There are no reports of controlled-trial-field 
studies with Leish-Tec®, but despite the lack of scientific publications, the 
vaccine was licensed in Brazil in 2008.
38
 
- DNA vaccines: several studies have been conducted with perspective of de-
velopment of DNA vaccines, that represent potential third generation vac-
cines against Leishmaniasis. They include antigen-encoding DNA plasmid 
vaccines and heterologous prime-boost vaccines.
28 
Compared to recombinant 
protein vaccines, DNA vaccines are much more stable and have the 
advantage of low production costs, no need for cold chain distribution, and 
the flexibility of combining multiple genes in a simple construct. A lot of 
interest has been generated for the development of a vaccine against 
leishmaniasis in recent years, with studies going on in the labs on 
experimental models. LACK, LeIF, TSA, LmSTI1, H1, CpA + CpB, KMP11, 
and NH36 are the most promising candidates that, since they have already 
been tested in various animal models. Immunization with HPB-LACK 
protected dogs against CanL by increasing the IFN-γ and IL-12 expression, 
lymphocyte proliferative response, and the IgG2 to IgG1 ratio, and it led to 
decreasing clinical symptoms, number of parasites in target tissues, and IL-4 
expression.
38
 
 
Until recently no vaccines were available in Europe. The LiESP/QA-21 vaccine 
(CaniLeish®, Virbac, France) was launched in Europe in 2011.
24, 25, 27, 37 
 
It is composed of Leishmania infantum excreted secreted proteins (ESP) and Quillaja 
saponaria purified extract as adjuvant.
 
It was found to induce an appropriate Th1-
dominated cell-mediated immune response after completing the primary course that 
is capable of reducing the parasite load in pre-infected macrophages in vitro.
24, 27, 37,39
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It has been demonstrated that the immune response induced by CaniLeish® is still 
present 1 year after the last injection of a primary vaccine course.
24, 25, 37 
 
 
3.3.4. CaniLeish® 
 
The LiESP/QA-21 vaccine (CaniLeish®) is available on the European marketplace 
since 2011.
24, 25, 27, 37
 The research was led by the Institut de Recherche pour le 
Développement (IRD) in France. 
The active substance is represented by Leishmania infantum Excreted-Secreted 
Proteins (ESP) which are characterized by a defined protein pattern. The Quillaja 
saponaria purified extract is used as adjuvant by reason of its immune stimulant 
properties that induce a strong Th1 immune cellular response, mainly mediated by 
the IFN-γ and IL2, and cytotoxc T-lymphocyte response. The regimen of vaccination 
recommends a primary course consisting of three injections at 3 weeks intervals in 
dogs at least 6 months old, and an annual booster immunisation with one dose of 
vaccine.
39
 The trend of the immune response is decisive for development of clinical 
illness or resistance to the disease. This last one seems to be associated with a 
Th1/Th2 mixed type immune response with Th1 cytokines predominance (IFN-γ, 
TNFα, IL2, IL3, IL12, IgG2). On the other hand, active disease is characterized by a 
marked humoral response.
24, 26, 27, 28, 29, 39
  
Several studies have demonstrated that vaccination with LiESP/QA-21 (CaniLeish®) 
induces a consistent seroconversion and predominant IgG2 profile against both 
Excreted-Secreted Proteins (ESP) and Promastigote Surface Antigen (PSA).
27, 37, 39 
 
CaniLeish® is capable of stimulating a strong and long-lasting cell-mediated 
immunity that is still present 1 year after the last dose of primary vaccine course.
24, 27, 
37, 39 
Especially, vaccination promotes the migration of dermal dendritic cells to draining 
lymph nodes and the presentation of Leishmania antigens to both CD4
+
 and CD8
+
 
cells, which consequently produce cytokines able to destroy the parasite by 
macrophage defences activation.
39
 
The vaccine, if used according to the recommended protocol, confers protection 
against Leishmaniasis by decreasing of active infection and clinical illness, reducing 
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the incidence of a potentially fatal disease in immunised dogs. Furthermore, since 
infectivity of dogs to the vector has been demonstrated to be correlated with the 
development of the disease, the reduction in the number of highly infectious dogs in 
the later stages could have advantageous impact on an epidemiological scale.
37, 39 
CaniLeish® was demonstrated to decrease approximately four-fold the risk to 
progress to symptomatic disease
25 
and even to reverse the course of an initial 
progression to active infection in exposed dogs showing subpatent infection (PCR 
positive and culture negative). Instead, as soon as the infection becomes an active 
one, the dog’s immune system loses the capability to hinder the active multiplication 
of the parasite, as it is illustrated in the scheme below (Figure 2).
24, 39
 
 
Figure 2: progression of Leishmaniasis in dogs 
 
 
For what concerns adverse side effects related to vaccination with CaniLeish®, the 
main potential risks include moderate and transient local reactions such as swelling, 
nodule, pain on palpation or erythema, that resolve spontaneously within 2 to 15 
days. Hyperthermia, apathy and digestive disorders lasting 1 to 6 days could be other 
commonly seen transient signs. Allergic-type reactions are considered uncommon.
39
 
Since the vaccine does not give 100% protection, it is advisable to combine the use 
of vaccine with additional preventative measures. 
34 
 
3.3.5. Conclusions 
 
CaniLeish® is a vaccine intended to reduce the incidence either of asymptomatic and 
symptomatic forms of Leishmania infection. Since it is now-a-day generally accepted 
that resistance to CanL is primarily dependent on development of an appropriate 
Th1-dominated cell-mediated immune response 
24, 26, 27, 28, 29, 37, 39
, the induction of a 
specific cell-mediated immunity by LiESP/QA-21 vaccine allows to reach the aim.
24, 
25, 26, 27, 29, 37, 39 
From the point of view of the Public Health, Leishmaniasis has been elected by the 
World Health Organization (WHO) among the diseases belonging to category-1, that 
include emerging and uncontrolled diseases.
28
 
Dogs are considered the main reservoir of Leishmania infection to humans. The 
development of the disease is correlated with an increase of dogs’ infectivity. 
Considering that CaniLeish® enables to reduce active infection, the use of the 
vaccine could be help to decrease the incidence of Human Visceral Leishmaniasis 
(HVL), consequently showing a beneficial impact on Public Health.
39
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EXPERIMENTAL PART 
 
INTRODUCTION 
 
The risk of Leishmania transmission through transfused blood products from canine 
blood donors is demonstrated to be possible due to its long incubation period, 
subclinical persistence in infected animals, and likelihood of remaining viable in 
bloodstocks.
1,29
 
Transmission of Leishmania by blood transfusion is most likely to occur in an 
endemic area, and it is important to highlight that also asymptomatic dogs can be 
infective.
21 
No test has 100% sensitivity and specificity, therefore the diagnosis of this infectious 
disease often requires an integrated approach that must include a history of exposure 
to vectors, an accurate physical examination aimed at highlighting of compatible 
clinical signs, haematological and biochemical evaluation and several methodologies 
to identify directly or indirectly the organism of interest.
4 
 
The Ministry of Health has recently revised the Italian guidelines about veterinary 
transfusion medicine and has stated that blood donor dogs should be healthy and 
should undergo complete clinical examination and laboratory tests, including 
haemato-biochemical profile, serological (IFAT) or molecular (PCR) assay for 
Leishmania infantum and some others infectious agents, namely Ehrlichia canis, 
Anaplasma phagocytophilum, Rickettsia rickettsii and Babesia canis. Specifically, 
PCR for Leishmania has been suggested as an additional screening test for 
Leishmania seronegative dogs.
21, 40, 41
 
In order to increase the prevention of Leishmaniasis in blood donors, vaccination 
could be used as additional preventative measure. 
 
Therefore, the aim of this study was to continue the previous study led at the 
Veterinary Transfusion Centre, Department of Veterinary Sciences, University of Pisa 
between February 2013 and July 2014, which evaluated haemato-biochemical and 
serological alterations in a group of healthy dogs participating in a voluntary blood 
donor program receiving a full coverage of immunization with CaniLeish®.
29 
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In this study, the monitoring, at established time checks, both of the same group of 
blood donor dogs of the previous study and of a new little group of dogs vaccinated 
between March 2015 and June 2016 has been arranged. 
It has been chosen to evaluate just the parameters that turned out more significant in 
the previous work29, namely Albumin, Total Proteins, Immunoglobulin G and IFAT 
values. As in the previous work, a rapid serological test (Speed Leish K™) was 
provided for screening of blood donor dogs before the vaccination.  
Furthermore, in the present study a molecular assay has been done and the results 
have been compared to serological results. Moreover, an additional acute-phase 
protein, namely C-Reactive Protein, has been evaluated. 
 
 
1 – MATERIALS AND METHODS 
 
1.1. Selection criteria 
The study took place between March 2015 and June 2016, carrying forward the 
previous work that was performed from February 2013 to July 2014. Upon written 
consent, they were included eighteen of the initial twenty-seven client-owned dogs 
participating in a voluntary blood donor program at the Veterinary Transfusion 
Centre, three new blood donor dogs and three non-blood donor dogs.  
The following selection criteria were used to include dogs as blood donors: Dog 
Erythrocyte Antigen (DEA) 1 negative, absence of any clinical signs or symptoms of 
disease, values of complete blood count (CBC) (ProCyte Dx®, Idexx, Italy) and 
blood smear examination, serum biochemical profile (SBP), including total protein, 
albumin, urea, alkaline phosphatase, and alanine aminotransferase (Liasys®, Assel, 
Italy), and serum protein electrophoresis (SPE) in agarose gel (Pretty®, Interlab, 
Italy) within the reference ranges of the Veterinary Clinical Pathology Laboratory, 
Dept. Veterinary Sciences, University of Pisa.  
Furthermore, any serological positivity titre for Leishmania infantum, Ehrlichia canis 
and Anaplasma phagocytophilum starting from 1:40 was a cause of exclusion from 
the blood donors program. Moreover, all dogs received a regular protection against 
ectoparasites, such as repellent and/or anti-feeding drugs applied locally. 
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1.1.1. Screening of blood donor dogs through Speed Leish K™  
Before starting the protocol of vaccination with CaniLeish®, blood donor dogs were 
evaluated on the base of criteria applied by the Veterinary Transfusion Centre 
previously reported in the selection criteria. Serological negativity for Leishmaniasis 
was also evaluated prior to administrate the vaccine using the rapid test Speed Leish 
K ™- Virbac, as suggested by the manufacturer company.  
Since the protective effect of CaniLeish® vaccine has not been studied in already 
infected dogs by Leishmania infantum, in the present study any positivity showed by 
Speed Leish K™ was an exclusion cause from administration of the vaccine. 
 
1.2. Vaccination of blood donor dogs with CaniLeish® 
Lyophilized CaniLeish® vaccine was stored at +4/+10°C, was reconstituted with 
1mL of its solvent and administered subcutaneously in the withers region followed 
by a gentle massage of the injection site.  
Dogs were monitored for 30 minutes in order to observe the onset of any possible 
reactions. The owners were advised to report to the authors any suspected reaction or 
adverse effect that might occur and in that case they would have undergone a control. 
The vaccine was administered according to the protocol indicated in the 
manufacturer’s instructions: first cycle of 3 inoculations, each of them every 3 
weeks, and annual boosters for further administration.  
In the present study the vaccine was also administrated for the second and third 
annual boosters. 
 
 
1.3. Study design 
 
Twenty-one canine blood donors (11 females, 10 males; 9 Boxers, 4 mixed breeds, 3 
Golden Retrievers, 2 Dobermanns, 1 Weimaraner, 1 Border Collie, 1 Newfoundland 
dog) and three non blood donor dogs (3 female Duchshunds) were included in this 
study.  
It was designed to continue the previous work29, monitoring both the original sample 
of dog blood donors that underwent the following stages of the vaccination cycle, 
namely the first, second and third annual boosters, and the new sample of dogs that 
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were immunized between March 2015 and June 2016.  
Compared to the original group, in this study the sample population is lacking in 4 
Boxers and 4 mixed breeds; instead, they have been added 2 Dobermanns, 1 
Newfoundland dog and 3 Duchshunds.   
The Times (T) of control were represented as follows: 
 T0 (basal blood sample, in conjunction with first immunization) 
 T1 (blood sample in conjunction with second immunization) 
 T2 (blood sample in conjunction with third immunization) 
 T3 (blood sample two months after the third immunization) 
 T4 (blood sample in conjunction with first annual booster) 
 T5 (blood sample in conjunction with second annual booster) 
 T6 (blood sample in conjunction with third annual booster)  
 
In the present study, dogs were included in a single population sample. In the group 
three subgroups were then identified according to the vaccination stages (T4-T6) that 
follow the first cycle of immunization. The difference in the vaccination stages 
between the three subgroups was due to the fact that the dogs had undergone the first 
immunization at different times. 
The three subgroups of the whole population sample were represented as follows: 
 Subgroup 1 included 5 dogs, which underwent the third annual booster (T6) 
 Subgroup 2 included 10 dogs, which underwent the second annual booster 
(T5) 
 Subgroup 3 included 7 dogs, which underwent the first annual booster (T4) 
 
 
Furthermore, another subgroup (subgroup 4) was identified and it was represented by 
dogs (6/24 of whole population sample) that underwent the first cycle of vaccination 
between March 2015 and June 2016, excluding those that had undergone the first 
immunization series during the previous study.  
The subgroup 2 includes two dogs that belong to subgroup 1 too, since they 
underwent both the second and the third annual boosters. In the same way, the 
subgroup 4 includes 2 dogs that belong to subgroup 3 too, since they underwent both 
the first vaccination cycle and the first annual booster. 
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In order to have an overview of trend of the parameters analysed in this study over 
the course of the time, we have also used, whenever possible, data collected in the 
previous work. This allowed us to increase the population size thus increasing 
statistical significance of the results. 
 
The assays that have been performed in this work include: some serum biochemical 
analytes (total protein, albumin, C Reactive Protein), serum electrophoresis, 
serological assays (IFAT L. infantum and Speed Leish K™) and molecular assay 
(PCR) for L.infantum. 
For the whole population some serum biochemical analytes (total protein and 
albumin), serum electrophoresis and serological assay (IFAT L.infantum) were 
performed. 
For the subgroups 1, 2, 3 and for the subgroup 4 at T3, in addition to the same 
laboratory tests performed for the whole population, C Reactive Protein and 
qualitative PCR were provided.  
For the whole population Speed Leish K™ was performed just at T0. 
 
 
1.4  Statistics  
 
Data distribution was assessed through the D’Agostino-Pearson test. The Kruskal-
Wallis test was performed for some serum biochemical analytes SBP and SPE. For 
all tests, significance was set at p < 0.05. Statistical analysis was performed using 
commercial software (MedCalc® Statistical Software version 15.8, Ostend, 
Belgium). 
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2 – RESULTS  
 
Selection Criteria: all dogs that have been included as blood donors were Dog 
Erythrocyte Antigen (DEA) 1 negative, and did not present any clinical signs or 
symptoms of disease. The complete blood count (CBC) and blood smear 
examination did not show any alteration. The serum biochemical profile (SBP), 
including total protein, albumin, urea, alkaline phosphatase, and alanine 
aminotransferase, and the serum protein electrophoresis (SPE) proved that the 
analytes were in the reference ranges of the Veterinary Clinical Pathology 
Laboratory, Dept. Veterinary Sciences, University of Pisa.  
Lastly, any serological positivity titre for Leishmania infantum, Ehrlichia canis and 
Anaplasma phagocytophilum starting from 1:40 was found. 
 
 
Serum Biochemical Analytes: slight hyperproteinemia up to the maximum value of 
the reference range (5.8-7.8 g/dL) occurred in 29.8% (28/94) of cases considering the 
whole monitoring period (T0-T6). As showed in Figure 3, the percentage of 
hyperproteinemia at each time-check was ranging from 21% at T0 to 46.6% at T1, 
36.8% at T2, 45.4% at T3, 6.6% at T4, 30% at T5 and 20% at T6. Nevertheless, as 
reported in Figure 4, the alterations of Total Protein did not turn out statistically 
significant differences (p = 0.34). 
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Figure 3: Percentage of hyperproteinemia at each time-check. 
 
 
 
 
Figure 4: Kruskal-Wallis test. Total Protein (g/dL): data distribution at each time-check. 
 
 
 
Serum Protein Electrophoresis: results from SPE are shown in Table 2 as absolute 
values using median and 95% confidence interval, and in Table 3 as percentage 
values using median and 95% confidence interval. 
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TABLE 2: Major serum proteins and electrophoresis fractions reported as absolute values. 
 
§ Values in brackets are reference ranges 
NT= Not Tested 
ND= Not Determinable due to  the small number of canine samples  
 
*Kruskal-Wallis test was p > 0.05 for all time-checks except where the asterisk next to the median  
values is reported (p < 0.05) 
 
 
 
  
 
 
 
 
 
Analyte§ Time Median 
95% CI  
median 
Analyte§ Time Median 
95% CI  
median 
Total Protein           
(5.8-7.8 g/dl) 
T0 7.1 6.7-7.7 
ß1-
globulins            
(0.3-1.0 
g/dl) 
T0 0.6* 0.6-0.7 
T1 7.6 6.8-9.1 T1 0.5* 0.4-0.5 
T2 7.4 6.6-8.6 T2 0.5* 0.4-0.5 
T3 7.4 6.8-10.0 T3 0.5* 0.3-0.8 
T4 7.2 6.9-7.3 T4 0.6* 0.4-0.9 
T5 7.7 7.0-8.5 T5 0.8* 0.5-1.1 
T6 7.6 ND T6    0.6 ND 
Albumin                    
(7.4-4.1 g/dl) 
T0 3.5 3.3-3.7 
ß2-
globulins            
(0.4-1.1 
g/dl) 
T0 0.7* 0.6-0.7 
T1 3.6 3.3-3.9 T1 1.0* 0.8-1.1 
T2 3.3 3.1-3.5 T2 1.0* 0.9-1.1 
T3 3.6 3.2-3.8 T3 0.9* 0.7-1.2 
T4 3.4 3.2-3.6 T4 0.8* 0.7-1.1 
T5 3.8 3.3-4.1 T5 0.8* 0.6-0.9 
T6 3.3 ND T6 1.3* ND 
α1-globulins            
(0.1-0,3 g/dl) 
T0 0.2 0.2-0.3 
γ-globulins               
(0.4-0.9 
g/dl) 
T0 0.5 0.5-0.7 
T1 0.2 0.2-0.25 T1 0.8 0.5-0.9 
T2 0.2 0.2-0.28 T2 0.7 0.6-0.7 
T3 0.2 0.2-0.3 T3 0.6 0.5-0.7 
T4 0.2 0.2-0.3 T4 0.7 0.6-0.8 
T5 0.2 0.2-0.3 T5 0.6 0.4-0.8 
T6 0.2 ND T6 0.8 ND 
α2-globulins            
(0.6-1.4 g/dl) 
T0 1.0 0.8-1.1 
C Reactive  
Protein  
(0.0-0.3 
mg/dl) 
T0 NT NT 
T1 1.1 0.9-1.2 T1 NT NT 
T2 1.0 1.0-1.1 T2 NT NT 
T3 1.1 0.9-1.2 T3 0.2* 0.1-0.3 
T4 1.0 1.0-1.2 T4 0.2* 0.0-0.5 
T5 1.3 1.0-1.5 T5 0.8* 0.2-1.3 
T6 1.0 ND T6 0.8* ND 
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TABLE 3: Major serum proteins and electrophoresis fractions reported as percentage values. 
 
§ Values in brackets are reference ranges 
NT= Not Tested 
ND= Not Determinable due to the small number of canine samples  
 
*Kruskal-Wallis test was p > 0.05 for all time-checks except where the asterisk next to the median  
values is reported (p < 0.05) 
 
 
 
  
 
 
Our data show a statistical significance (p < 0.05) of some electrophoresis fractions, 
namely  -1-globulins (as absolute and percentage values),  -2-globulins (as absolute 
and percentage values) and the C Reactive Protein (mg/dL). The statistical 
significance of  γ-globulins (%) appears borderline (p = 0.052). 
The related Connected-line graphs (Figure 5, 7, 9, 11, 13, 15) and Box-and-Whisker 
graphs (Figure 6, 8, 10, 12, 14, 16) are reported below. 
 
 
Analyte§ Time Median 
95% CI 
median 
Analyte§ Time Median 
95% CI 
median 
Albumin                  
(47.5-58.5 %) 
T0 53.5 48.5-56.2 
ß1-globulins            
(5.9-13.3 %) 
T0 9.9* 8.7-11.7 
T1 51.3 48.0-56.3 T1 6.7* 5.4-7.7 
T2 49.5 47.5-52.6 T2 7.1* 6.1-7.5 
T3 51.3 48.2-53.4 T3 7.9* 5.6-11.9 
T4 48.0 45.8-52.0 T4 8.9* 5.7-13.7 
T5 50.0 44.4-53.0 T5 9.7* 8,0-15.4 
T6 47.7 ND T6 8.1 ND 
α1-globulins            
(2.6-4.4 %) 
T0 3.8 3.2-4.0 
ß2-globulins              
(7.2-14.4 %) 
T0 11.1* 9.0-11.6 
T1 3.3 2.9-3.8 T1 14.3* 13.1-15.5 
T2 3.3 3.0-3.9 T2 15.3* 13.9-15.6 
T3 3.3 2.9-3.5 T3 12.6* 10.4-16.9 
T4 3.4 3.1-3.9 T4 11.5* 11.0-15.3 
T5 3.4 3.1-4.8 T5 10.3* 9.3-11.5 
T6 3.2 ND T6 16.6* ND 
α2-globulins            
(10.7-18.0 %) 
T0 14.7 12.6-16.1 
γ-globulins 
(6.6-11.6 %) 
T0 8.5* 6.6-9.8 
T1 15.0 12.3-16.3 T1 11.0* 8.0-12.2 
T2 14.6 13.2-17.0 T2 10.2* 8.8-11.8 
T3 14.9 13.5-16.7 T3 8.7* 6.8-9.8 
T4 15.2 14.2-15.6 T4 10.3 9.0-11.0 
T5 16.8 14.4-19.2 T5 7.5* 6.7-11.5 
T6 14.5 ND T6 10.5 ND 
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Figure 5: Kruskal-Wallis test.  -1-globulins (g/dL): trend of medians. 
 
 
 
Figure 6: Kruskal-Wallis test.  -1-globulins (g/dL): statistical correlations among time-checks. 
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The  -1-globulins (g/dL) Box-and-Whisker graph shows that there is a statistically 
significant difference among the time-checks as follows: 
 T0 with T1 and T2 
 T1 with T0 and T5 
 T2 with T0, T4 and T5 
 T3 with T5 
 T4 with T2 and T5 
 T5 with T1, T2, T3 and T4 
 
 
 
  
Figure 7: Kruskal-Wallis test.  -1-globulins (%): trend of medians. 
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Figure 8: Kruskal-Wallis test.  -1-globulins (%): statistical correlations among time-checks. 
 
 
 
 
The  -1-globulins (%) Box-and-Whisker graph shows that there is a statistically 
significant difference among the time-checks as follows: 
 T0 with T1 and T2 
 T1 with T0 and T5 
 T2 with T0, T4 and T5 
 T3 with T5 
 T4 with T2 
 T5 with T1, T2 and T3 
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Figure 9: Kruskal-Wallis test.  -2-globulins (g/dL): trend of medians. 
 
 
 
 
 
Figure 10: Kruskal-Wallis test.  -2-globulins (g/dL): statistical correlations among time-checks. 
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The  -2-globulins (g/dL) Box-and-Whisker graph shows that there is a statistically 
significant difference among the time-checks as follows: 
 T0 with T1, T2, T3, T4 and T6 
 T1 with T0 and T5 
 T2 with T0 and T5 
 T3 with T0 
 T4 with T0 
 T5 with T1, T2 and T6 
 T6 with T0 and T5 
 
 
 
 
Figure 11: Kruskal-Wallis test.  -2-globulins (%): trend of medians. 
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Figure 12: Kruskal-Wallis test.  -2-globulins (%): statistical correlations among time-checks. 
 
 
 
 
The  -2-globulins (%) Box-and-Whisker graph shows that there is a statistically 
significant difference among the time-checks as follows: 
 T0 with T1, T2, T3, T4 and T6 
 T1 with T0 and T5 
 T2 with T0 and T5 
 T3 with T0 and T5 
 T4 with T0 and T5 
 T5 with T1, T2, T3, T4 and T6 
 T6 with T0 and T5 
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Figure 13: Kruskal-Wallis test. γ-globulins (%): trend of medians. 
 
 
 
 
 
Figure 14: Kruskal-Wallis test. γ-globulins (%): statistical correlations among time-checks. 
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The γ-globulins (%) Box-and-Whisker graph shows that there is  a borderline 
statistically significant difference (p = 0,052) among the time-checks as follows: 
 T0 with T1 and T2 
 T1 with T0 and T3 
 T2 with T0, T3 and T5 
 T3 with T1 and T2 
 T5 with T2 
 
 
 
 
 
Figure 15: Kruskal-Wallis test. C Reactive Protein (mg/dL): trend of medians. 
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Figure 16: Kruskal-Wallis test. C Reactive Protein (mg/dL): statistical correlations among time-
checks. 
 
 
The C Reactive Protein (mg/dL) Box-and-Whisker graph shows that there is a 
statistically significant difference among the time-checks as follows: 
 T3 with T5 and T6 
 T4 with T5 and T6 
 T5 with T3 and T4 
 T6 with T3 and T4 
An increase of C Reactive Protein values was recorded in 60.7% (17/28) of cases 
(Table 4). Out of this percentage, C Reactive Protein values were 4 times the 
laboratory cut-off level in 10.7% (3/28) of cases, and between the threshold and 4 
times the threshold in 50% (14/28) of cases.  
Out of the percentage of dogs that showed values 4 times the laboratory cut-off level, 
67% of cases were at T5 and the remaining 33% were at T6. For what concerns the 
percentage of dogs that showed C Reactive Protein values between the threshold and 
4 time this one, 42.8% of cases were at T5, 21.4% were both at T4 and at T6, and the 
remaining 14.2% were at T3.  
However, just C Reactive Protein has been analysed, and remaining proteins that 
migrate in each fraction should be investigated individually. 
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TABLE 4: C Reactive Protein (mg/dL)*. Number of dogs for each range of values. 
Time-checks Values in reference range 
Values ≥ thre-
shold  
Values ≥ 4 times thre-
shold 
T3 (n=6) 4  2 / 
T4 (n=7) 4 3 / 
T5 (n=10) 2 6 2 
T6 (n=5) 1 3 1 
*Reference range: 0,0-0,3 (mg/dL) 
 
 
 
Serological Tests: a qualitative rapid test (Speed Leish K™) was performed at T0 for 
the whole population sample, and all assays were negative.  
The results of IFAT are reported in Table 5 (and Figure 17 and 18). Considering the 
whole monitoring time (T0-T6), the canine samples were negative in 73.3% (77/105) 
of cases and positive in 26.7% (28/105). Out of the percentage of samples with 
positive IFAT titres, 9.5% showed titres of 1/40, 8.6% showed titres of 1/80, 6.7% 
showed titres of 1/160 and 1.9% showed titres of 1/320. 
Out of the percentage of dogs that presented IFAT titres of 1/40, 30% of cases were 
at T3, 20% were both at T4 and T5 and T6, and remaining 10% of cases were at T0. 
 
Out of the percentage of dogs that presented IFAT titres of 1/80, 44.5% of cases were 
at T2, 33.3% were at T3, and 11.1% were both at T1 and T4. 
 
For what concerns the percentage of canine samples that showed IFAT titres of 
1/160, 42.9% of cases were both at T1 and T2, and 14.2% were at T4. 
 
Lastly, out of the 1.9% of dogs that presented IFAT titres of 1/320, 50% of cases 
were at T2 and remaining 50% were at T4. 
 
 
54 
 
 
TABLE 5: IFAT titres for L.infantum at each time-check. 
 
Colonna1 
Negative 1/40 1/80 1/160 1/320 
T0 (n=22) 21 (95.5%) 1 (4.5%) / / / 
T1 (n=19) 15 (78.9%) / 1 (5.2%) 3 (15.8%) / 
T2 (n=18) 10 (55.5%) / 4 (22.2%) 3 (16.6%) 1 (5.5%) 
T3 (n=11) 5 (45.4%) 3 (27.4%) 3 (27.3%) / / 
T4 (n=17) 12 (70.6%) 2 (11.8%) 1 (5.9%) 1 (5.9%) 1 (5.9%) 
T5 (n=13) 11 (84.6%) 2 (15.4%) / / / 
T6 (n=5) 3 (60%) 2 (40%) / / / 
 
 
 
 
 
 Figure 17: IFAT titres for L.infantum. T0-T6 
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 Figure 18: IFAT titres for L.infantum. T3-T6 
  
 
The histograms above display that the percentage of negative IFAT titres decrease 
from T0 up to T3, increase again up to T5 and lastly undergo a further decrease from 
T5 up to T6.  
 
 
Molecular assay: For the subgroups 1, 2, 3 and 4 at T3 qualitative PCR was 
provided. The results are reported in Table 6 and Figure 19. The canine samples were 
negative in 92.3% (24/26) of cases and positive in 7.7% (2/26) of cases. Out of the 
percentage of dogs that resulted positive, 50% of cases were at T3 and the other 50% 
were at T4.  
 
 
TABLE 6: qualitative PCR results. 
 
Colonna1 
Negative Positive 
T3 (n=6) 5 (83%) 1 (17%) 
 T4 (n=7) 6 (86%) 1 (14%) 
T5 (n=8) 8 (100%) / 
 T6 (n=5) 5 (100%) / 
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 Figure 19: qualitative PCR results 
 
 
The concordance rate between IFAT titres and results of qualitative PCR is reported 
in Figure 20. Only the IFAT results for the subgroups (1, 2, 3 and 4 at T3) for which 
PCR was provided were considered. 
The histogram displays that the canine samples showed negative IFAT titres in 65.4% 
of cases (17/26), and that out of this percentage 94% of dogs showed negative PCR 
(16/17), whereas 6% (1/17) of dogs presented positive PCR. It reveals 94% of 
concordance rate between the serological and molecular assays. 
 
IFAT titre of 1/40 and 1/80 was presented respectively in 15.4% (4/26) and 11.5% 
(3/26) of cases. Out of these percentages, 100% of dogs showed negative PCR 
(100% of concordance rate).  
 
IFAT titre of 1/160 was demonstrated in 3.8% of donor dogs (1/26), and out of this 
percentage 100% of dogs showed positive PCR (100% of concordance rate). 
 
Lastly, 3.8% of canine samples (1/26) revealed IFAT titre of 1/320, but PCR resulted 
negative, (0% of concordance rate).  
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Figure 20: concordance rate between IFAT titres and qualitative PCR. 
 
  
For a better survey, additional Complete Serum Biochemical Profile and Serum 
Protein Electrophoresis to the two blood donor dogs that showed positive PCR were 
provided.  
The Serum Biochemical Profiles did not reveal significant alterations (data not 
shown). 
The Serum Protein Electrophoresis diagrams (Figure 21 and 22) display a minimal 
increase of  1-,  2- and α1-globulins. 
The typical Serum Protein Electrophoresis diagram of Leishmaniosis is reported in 
Figure 23 and shows the characteristic polyclonal globulinopathies in the  - γ region. 
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Figure 21: Serum Protein Electrophoresis (SPE) diagram of blood donor dog presenting positive PCR 
at T3 
 
 
 
 
 
 
 
 
Figure 22: Serum Protein Electrophoresis (SPE) diagram of blood donor dog presenting positive PCR 
at T4. 
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Figure 23: Typical polyclonal β- and γ –globulins modifications in Canine Leishmaniasis.45  
  
 
 
3 – DISCUSSIONS 
 
Serum Biochemical Analytes and SPE  
 
The plasma protein profile is considered one of the most reliable markers to be used 
for monitoring Leishmaniasis. Total protein concentrations are markedly increased in 
infected dogs and can reach more than 10 g/dl. This increase is mainly due to high 
levels of β- and γ-globulins, which often show a typical electrophoretic pattern, 
characterized by hyperproteinaemia, polyclonal hypergammaglobulinaemia and an 
inversion of the albumin/globulin ratio.  Following renal or hepatic damage, a drastic 
fall in albumin levels can be observed.
44,45
  
Hyperglobulinaemia is a common laboratory finding and is almost always associated 
with hypoalbuminaemia.   and γ fractions are mainly involved, due to the polyclonal 
lymphatic activation.
46 
 
The increase of total serum protein and γ globulins is demonstrated to be more 
common in dogs presenting clinical signs of Leishamniasis. The concentration of 
Ceruloplasmin, C Reactive Protein and Haptoglobin seems to be more sensitive for 
detection of the asymptomatic infected dogs. However, a high false-positive rate 
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would be expected since there are many other conditions which show an increase of 
the acute phase proteins, such as surgery, steroid treatments, infectious and parasitic 
diseases and other inflammatory processes.
44
  
Indeed,   and γ globulin fractions include α-2-macroglobulin, Haptoglobin, 
Transferrin and C Reactive Protein, that are acute phase inflammatory proteins.
43
 
Since our data did not show alterations in total protein concentration and  -γ 
globulin fractions comparable with typical Leishmaniasis pattern, the significance of 
these results is likely due to an acute phase inflammatory response subsequent to 
inoculation of the vaccine, and also due to the development of a post vaccination 
immunity.
 24, 25, 26, 27, 29, 37, 39 
However, just C Reactive Protein has been analysed, and remaining proteins that 
migrate in each fraction should be investigated individually. 
  
 
Serological Tests 
 
Before starting the protocol of vaccination with CaniLeish®, serological negativity 
of blood donor dogs for Leishmaniasis was evaluated prior to administrate the 
vaccine using the rapid test Speed Leish K ™- Virbac, as suggested by the 
manufacturer company. In this study, Speed Leish K™ was performed at T0 for the 
whole population sample, and all assays were negative. In the previous study, Speed 
Leish™ was performed at all time-checks and all assays remained negative.29 
Speed Leish K™ detects specifically antibodies against the kinesins of Leishmania, 
which are not present in Excreted-Secreted Proteins (ESP) of CaniLeish® vaccine. 
Therefore, Speed Leish K™ allows both to evaluate the absence of anti-Leishmania 
antibodies before starting the first vaccination cycle and does not detect the 
antibodies induced by the vaccine.
19,42
  
However, Solano-Gallego et al. have reported that the qualitative rapid test showed 
low sensitivity in infected subclinical dogs. Thus, these false negative results may 
induce to immunize by vaccine seropositive dogs, and it could represent a 
complicating factor for evaluation of the vaccine efficacy in field.
29,47 
Anyhow, in our study all blood donor dogs had negative IFAT titres at T0.  
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For what concerns the IFAT results, our data show that percentage of negative IFAT 
titres decrease from T0 up to T3, increase again up to T5 and lastly undergo a further 
decrease from T5 up to T6.  
In accordance with many previous studies, our data record an increase of IFAT titre 
subsequently to vaccination (T0-T3) up to the seroconversion and then a gradual 
decrease. Furthermore, also the trend of humoral immune response after the first 
annual booster (T4-T6), which is showed to be similar to the transient profile after 
the first cicle of vaccination,  turned out to match with that obtained in the previous 
studies.
29 
However, serological studies are characterized by a high coefficient of variation 
inter-and intra-assay. Furthermore, serological tests are non-specific tests and they do 
not distinguish antibodies due to infection by those subsequent the 
immunization.
19,29,42
 For this reason, the IFAT results should be interpreted with 
caution in vaccinated dogs. Standard guidelines suggest considering as high only 
titres exceeding at least fourfold difference with threshold value of positivity for the 
reference laboratory.
7,29  
Therefore, although 6.7% of blood donor dogs showed titres of 1/160 and 1.9% 
showed titres of 1/320 in our study, these values should not be considered a sure 
proof of infection based on the standard guidelines suggestion, and the increase of 
IFAT titres recorded by our data is more likely due to humoral immune response 
developed after the vaccination. 
 
 
Molecular Test 
 
Nowadays, it is widely known in the scientific literature that the most useful 
diagnostic approach for investigation of Leishmaniasis include both the detection of 
specific antibodies against L.infantum through serological assays and to evidence the 
parasite DNA through molecular techniques.
5,15,23,29
 
Therefore, qualitative PCR was provided. In our study, the canine samples showed 
negative PCR in 92.3% of cases and positive PCR in 7.7%. Out of the percentage of 
dogs that resulted positive, 50% of cases were at T3 and the other 50% were at T4.  
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The concordance rate between IFAT titres and results of qualitative PCR has been 
evaluated. Only the IFAT results for the subgroups (1, 2, 3 and 4 at T3) for which 
PCR was provided were considered. 
As previously stated, standard guidelines suggest considering as high only titres 
exceeding at least fourfold difference with threshold value of positivity for the 
reference laboratory (generally values ≥ 1/80)7,29.  
From our data it is turned out that there is 94% of concordance rate between negative 
IFAT titres and PCR results (negative), whereas 6% of dogs showed positive PCR.  
IFAT titres of 1/40 and 1/80 revealed 100% of concordance rate with PCR results 
(negative). 
IFAT titres of 1/160 and 1/320 resulted in 100% positive and negative PCR 
respectively.  
Although the IFAT titres of 1/160 and 1/320 are not considered indicative of 
infection on the base of the standard guidelines, they are anyhow higher then the 
threshold value of positivity for  the reference laboratory. Therefore, the concordance 
rate between IFAT and PCR results could be considered of 100% and 0% 
respectively.  
For a better survey, additional Complete Serum Biochemical Profile and Serum 
Protein Electrophoresis in the two blood donor dogs that showed positive PCR were 
provided.  
The Serum Biochemical Profile did not reveal significant alterations (data not 
shown), and SPE diagrams did not show abnormalities compatible with those typical 
of infected or sick individuals, characterized by polyclonal gammopathy and/or β-γ 
bridging.
15 
 
However, studies evaluating PCR from different tissues of infected dogs have shown 
variable results that could be explained by the heterogeneous distribution of the 
parasites in each tissue, Leishmania strain’s tropism and local immune response.16, 17 
Therefore, the selection of the site’s sample for PCR assay is a very important matter. 
Lymph node biopsy has high sensitivity, but sampling could be not easy in absence 
of lymphoadenomegaly; bone marrow aspirates are an appropriate alternative, but 
collection is invasive. Instead, the sensitivity obtained from blood sample is lower 
when compared with the other tissues.
22
 
Nevertheless, the detection of DNA of Leishmania not always represents clinical 
disease, but may also show the presence of unviable organisms.
21
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However, as previously mentioned, the low sensitivity of qualitative rapid test 
(Speed Leish K™) in infected subclinical dogs reported by some authors, may result 
in vaccination of seropositive dogs and it could represent a complicating factor for 
evaluation of the vaccine efficacy in field.
29,47
  
For a better investigation, quantitative real-time PCR should be performed. 
 
 
 
4 – CONCLUSIONS 
 
Transfusion of whole blood and its byproducts is considered important for the 
survival of more than 80% of canine patients in critical conditions. Overall risks 
associated with transfusions include the chance of diseases transmission. Appropriate 
screening of blood donors for blood-borne infectious disease agents should be 
performed to reduce this risk. Leishmania infantum can be experimentally 
transmitted by whole blood or mononuclear cell fractions of infected dogs to 
recipient animals, and this is a significant finding given the widespread use in 
veterinary medicine of blood transfusions.  
In this study, a group of healthy blood donor dogs has been monitored over the time 
in order to detect possible post vaccination abnormalities. Our data have shown that 
after immunization with CaniLeish® occurred only minimal modification in total 
protein concentrations, some globulins fractions and mild increase of IFAT titres.  
The significance of these results is likely due to an acute phase inflammatory 
response subsequent to inoculation of the vaccine, and also due to the development 
of post-vaccination immunity. Just 7.7% of dogs showed positive PCR, but from the 
additional assays did not occur any evidence of disease. 
In order to conduct a right clinical-pathological evaluation both in vaccinated and 
unvaccinated dogs, all tests should be interpreted on the base of context. 
The limits of our study were the low number of canine samples included, their 
different vaccination stages and the lack of quantitative real-time PCR. 
In conclusion, the use of the vaccine CaniLeish® could be a safe and important 
practice, especially in the field of canine transfusion medicine. 
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